Connect with us
[ad_1] Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash. Continue reading this article with a Barron’s subscription. View Options...
[ad_1] By Anthony O. Goriainoff AstraZeneca said Thursday that its and MSD’s Lynparza cancer treatment had been approved in the U.S. for the treatment of metastatic...
[ad_1] Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t...
[ad_1] By Joe Hoppe AstraZeneca PLC said Monday that it has agreed to buy CinCor Pharma, Inc., acquiring global rights to the latter’s baxdrostat cardiorenal drug...